Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
On March 6, 2023, the Drug Enforcement Administration published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin- 4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as brorphine), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. In an amendatory instruction, the document incorrectly designated certain paragraphs. This document corrects that instruction.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 137 (Wednesday, July 19, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 137 (Wednesday, July 19, 2023)]
[Rules and Regulations]
[Page 46073]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-15249]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-716]
Schedules of Controlled Substances: Placement of Brorphine in
Schedule I; Correction
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order; correction. Correcting amendment.
-----------------------------------------------------------------------
SUMMARY: On March 6, 2023, the Drug Enforcement Administration
published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin-
4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as
brorphine), including its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers whenever the existence of such isomers,
esters, ethers, and salts is possible within the specific chemical
designation, in schedule I of the Controlled Substances Act. In an
amendatory instruction, the document incorrectly designated certain
paragraphs. This document corrects that instruction.
DATES: This correcting amendment is effective July 19, 2023, and is
applicable beginning March 6, 2023.
FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and
Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION: In FR Doc. 2023-04364, appearing on page
13692 in the Federal Register of Monday, March 6, 2023 (88 FR 13692),
the following correction is made:
Sec. 1308.11 [Corrected]
0
1. On page 13694, in the third column, amendatory instruction number 2
is corrected to read as follows:
0
``2. In Sec. 1308.11:
0
a. Redesignate paragraphs (b)(22) through (b)(92) as (b)(23) through
(b)(93);''
0
b. Add a new paragraph (b)(22);
0
c. Remove and reserve paragraph (h)(49).
The addition reads as follows:''
Signing Authority
This document of the Drug Enforcement Administration was signed on
July 5, 2023, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-15249 Filed 7-18-23; 8:45 am]
BILLING CODE P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.